C. Dubos

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.

N. Girard, J. Mazières, C. Lindsay, 2016, Lung cancer.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

L. Misery, C. Robert, L. Chiche, 2019, Arthritis & rheumatology.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

O. Molinier, D. Moro-Sibilot, F. Barlesi, 2020, Clinical lung cancer.

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

F. Barlesi, P. Fournel, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.

R. Gervais, P. Dô, J. Michels, 2016, Lung cancer.